Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             244 results found
no title author magazine year volume issue page(s) type
1 A case of levodopa responsive parkinsonism due to methanol toxicity, an impact of COVID-19 crisis Shah, M.
113 S p.
 article
2 Aceruloplasminemia - ultra-rare cause of iron accumulation Antos, A.
113 S p.
 article
3 A comprehensive study of the association between autonomic and clinical severity in spinocerebellar ataxia type 3 patients Tamuli, D.
113 S p.
 article
4 A Croatian tertiary center experience on the impact of the COVID-19 pandemic on Parkinson's disease: a cross-sectional telephone study Hero, M.
113 S p.
 article
5 Addressing fear of falling avoidance behavior in Parkinson’s disease: a theoretical framework to inform clinical practice Landers, M.R.
113 S p.
 article
6 Advanced therapies for Parkinson's disease (PD) in the age of telehealth Mari, Z.
113 S p.
 article
7 Adverse effects of levodopa/carbidopa intrajejunal gel treatment: a single center long-term prospective study Premzl, M.
113 S p.
 article
8 A late-onset mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) case with Parkinsonism Saltoğlu, T.
113 S p.
 article
9 Alterations in the HSP70 system in PBMC accompanying Parkinson's disease Vavilova, J.
113 S p.
 article
10 Alterations of brain neurotransmitters and metabolites in a rat model of Huntington’s disease Kumar, A.
113 S p.
 article
11 Amantadine treatment in Parkinson’s disease patients as a modulatory factor of SARS-Cov-2 infection Szlufik, S.
113 S p.
 article
12 A multimodal meta-analysis of structural and functional brain changes in idiopathic blepharospasm Zhang, M.
113 S p.
 article
13 Analysis of MRT results in Parkinson's disease, vascular Parkinsonism and chronic ischemia of the brain Umirov, A.
113 S p.
 article
14 An experimental paradigm for testing effect of alternating-frequency deep brain stimulation on gait, in Parkinson disease Liao, J.
113 S p.
 article
15 A novel C19ORF12 mutation in a MPAN family with the treatment of deferiprone Chen, S.
113 S p.
 article
16 A novel summary index derived from Kinect to evaluate the severity of postural abnormalities in patients with Parkinson’s Disease Hong, R.
113 S p.
 article
17 A novel treatment for Apraxia of Eyelid Opening using a pulsating headband: a single-centre pilot study Arjun, S.
113 S p.
 article
18 Antiemetics may not be necessary for titration of apomorphine sublingual film for the treatment of "OFF" episodes in Parkinson's disease Hauser, R.A.
113 S p.
 article
19 Anti-Ri associated ophthalmoplegia, ataxia and spastic tetraparesis revealing breast cancer Moura, J.
113 S p.
 article
20 Apomorphine sublingual film does not worsen dyskinesia in the long-term treatment of “OFF” episodes in Parkinson’s disease Klos, K.J.
113 S p.
 article
21 Apomorphine sublingual film for “OFF” episodes in Parkinson’s disease: analysis of baseline factors Nicholas, A.P.
113 S p.
 article
22 Apomorphine sublingual film for “OFF” episodes in Parkinson’s disease: long-term safety and efficacy Factor, S.
113 S p.
 article
23 Apomorphine sublingual film has minimal effect on impulse control disorders in long-term treatment of “OFF” episodes in Parkinson’s disease Espay, A.
113 S p.
 article
24 Application of the Chinese version of the Montreal cognitive assessment-basic for assessing Mild Cognitive Impairment in Parkinson’s disease Chen, W.
113 S p.
 article
25 Assessment of bilirubin levels in Parkinson's disease Tur, E. Kobak
113 S p.
 article
26 Assessment of pain syndrome in Parkinson's disease in Uzbekistan Goyibova, G.
113 S p.
 article
27 Association between plasma cytokines and motor, non-motor symptoms in Parkinson’s disease Abdurakhmonova, K.
113 S p.
 article
28 A Swedish SCA34 family with late onset ataxia, cerebellar atrophy and ocular movement abnormalities with a novel mutation in ELOVL4 Dobloug, S.
113 S p.
 article
29 Attainment of physiologic salivary flow rate with long-term incobotulinumtoxinA treatment for sialorrhea in Parkinson’s disease and other neurologic conditions Jost, W.
113 S p.
 article
30 Autonomic nervous system dysfunction in cases of neurodegeneration associated with mutations in C19orf12 Skowronska, M.
113 S p.
 article
31 Autophagy-lysosomal and mitochondrial polygenic risk scores in Parkinson's disease Dehestani, M.
113 S p.
 article
32 Belly dancer’s dyskinesia: case report Carus, K.I.
113 S p.
 article
33 Benefit of multiple incobotulinumtoxinA injections for pain reduction in adult patients with limb spasticity: pooled analysis of phase 2/3 studies Wissel, J.
113 S p.
 article
34 Bezoar And Catheter Knotting As Rare Complications Of Levodopa Carbidopa Intestinal Gel Therapy Saltoğlu, T.
113 S p.
 article
35 Biomarkers for Parkinson’s Disease with Reflex Tears Stratified by Disease Duration Lew, M.
113 S p.
 article
36 Biomarkers of Parkinson's disease Kondybayeva, A.
113 S p.
 article
37 Biopsychosocial aspect of patients with X-Linked Dystonia-Parkinsonism: Its implications on quality of life Alcachupas, A.
113 S p.
 article
38 Botulinum toxin type a for blepharospasm Duarte, A.
113 S p.
 article
39 Brain atrophy correlates with neuropsychological examination in Parkinson’s disease patients Szlufik, S.
113 S p.
 article
40 Brittle dyskinesias after bilateral STN DBS: dissociation of microlesioning effect on tremor versus on dyskinesias Mari, Z.
113 S p.
 article
41 Burning mouth syndrome to oral cenesthopathy: a spectrum of neuropsychiatric and sensory complications in neurodegenerative parkinsonism Yu, J.R.T.
113 S p.
 article
42 Can restless legs syndrome be a predictor of parkinsonism in patients with migraine comorbid with hypertension? Gulova, M.
113 S p.
 article
43 Carrier mediated delivery system bearing dopamine for effective management of parkinsonism Bhargava, M.
113 S p.
 article
44 Cavernous sinus thrombosis in patients after coronavirus disease patients with vascular parkinsonism in Uzbekistan Bobamuratova, D.
113 S p.
 article
45 Cervical dystonia with cerebellar ataxia in KCNA1 mutation: a phenotypic expansion Mahale, R.
113 S p.
 article
46 Characteristic of impulse control disorders in Polish patients with Parkinson's disease Toś, M.
113 S p.
 article
47 Characteristics of tics in follow-up study of community-based high risk cohort of 2511 children Szejko, N.
113 S p.
 article
48 Charcot-Marie-Tooth Disease associated with Parkinson Disease, about a case Pacheco Mendoza, H.
113 S p.
 article
49 Cholinergic brain network deficits associated with vestibular sensory conflict deficits in Parkinson's disease: correlation with postural and gait deficits Bohnen, N.
113 S p.
 article
50 Clinical and neurophysiological features of sensory dysfunction in Parkinson's disease patients in Uzbekistan Kurbonov, S.
113 S p.
 article
51 Clinical aspects of patients with blepharospasm in Latvia: one center study Kalniņa, M.
113 S p.
 article
52 Clinical characteristic of hemifacial spasm patients in Latvian population Dubra, A.
113 S p.
 article
53 Clinical correlations of Parkinson’s disease and vascular parkinsonism: a retrospective review from Uzbekistan Umarov, A.
113 S p.
 article
54 Clinical evaluation of neuropsychiatric symptoms in patients with Parkinson’s disease during COVID-19 pandemic: risk factors Salokhiddinov, M.
113 S p.
 article
55 Clinical milestones demonstrate compression of morbidity in patients with Parkinson`s disease treated by deep brain stimulation of the subthalamic nucleus Schnalke, N.
113 S p.
 article
56 Clinical presentation and diagnosis of a rare brain disease – progressive supranuclear palsy Angelova, A.
113 S p.
 article
57 Clinical presentation, comorbidities and treatment of GAD antibodies associated Stiff Person Syndrome Lazzeri, G.
113 S p.
 article
58 Clinical tremor-study with gender features in patients with essential tremor in Uzbekistan Goyibova, G.
113 S p.
 article
59 Common pitfalls in recognition of an age old malady: edentulous stereotypy Desai, S.
113 S p.
 article
60 Compared effects of magnetic-resonance guided ultrasound (MRgFUS) and deep brain stimulation (DBS) in a 58 year old Parkinson's disease patient Papić, E.
113 S p.
 article
61 Comparing the features of cervical dystonia subtypes: a retrospective study in Pakistan Fatima, A.
113 S p.
 article
62 Comparison of autonomic dysfucntion in patients with Parkinson’s disease and progressive supranuclear palsy Malkiewicz, J.
113 S p.
 article
63 Comparison of autonomic dysfunction in essential tremor and Parkinson’s disease: a pilot study Malkiewicz, J.
113 S p.
 article
64 Comparison of patient preferences for Parkinson’s disease treatments and reductions in OFF-time Serbin, M.
113 S p.
 article
65 Comparison of pharmacokinetics of apomorphine (sublingual film or subcutaneous injection) between patients with Parkinson's disease in Europe and North America Agbo, F.
113 S p.
 article
66 Comparison of voice parameters, self-assessment of speech and sialorrhea levels in Parkinson's disease patients with and without swallowing problems Sapmaz Atalar, M.
113 S p.
 article
67 Continuous wavelet transforms to improve the accuracy of motor assessments of Parkinson’s disease Kosuri, T.
113 S p.
 article
68 Correlation analyses of serum cytokine in Parkinson's disease and Parkinsonism-plus syndrome Chen, X.
113 S p.
 article
69 Correlation between age and positive and negative affect in Parkinson’s disease Almaraz-Espinoza, A.
113 S p.
 article
70 Correlation between NREM Sleep EEG characteristics and Mild Cognitive Impairment in patients with Parkinson’s disease Abdurakhmonova, K.
113 S p.
 article
71 Correlation-gender features in patients with Huntington’s disease in Uzbekistan Umarov, A.
113 S p.
 article
72 Correlation of hypothalamic-pituitary adrenal disorders with cognitive impairment in Parkinsons disease and vascular parkinsonism Akramova, D.
113 S p.
 article
73 Correlation of olfactory dysfunction with behavioral symptoms in tremor predominant (TDT) versus akinetic rigid (ART) Parkinson's disease Panambur, S.
113 S p.
 article
74 Correlation specificity of neuroimaging changes with clinic syndromes in Parkinson's disease, vascular parkinsonism and chronic cerebral ischemia Khamdamov, S.-J.
113 S p.
 article
75 Critical Appraisal of Economic Evaluation of Biomarkers Used for Screening of Dementia Azharuddin, M.
113 S p.
 article
76 Data of P. Stradins Clinical University Hospital Dystonia Register: time from symptoms to diagnosis and treatment of blepharospasm Kalniņa, M.
113 S p.
 article
77 Deep brain stimulation of posterior subthalamic area for Holmes Tremor Kamo, H.
113 S p.
 article
78 Depression impact on subjective and objective severity of cervical and segmental dystonia Meļņikova, V.
113 S p.
 article
79 Design of the Remote Optimization Adjustment and Measurement for Deep Brain Stimulation (ROAM-DBS) randomized prospective outcomes study of remote programming Tomlinson, T.
113 S p.
 article
80 Detection of Parkinson's disease using a deep neural network based on gait analysis Bajpai, A.
113 S p.
 article
81 Development of a voice and motor speech assessment protocol across an academic health center Rountrey, C.
113 S p.
 article
82 Development of osteomyelitis after COVID 19 in patients with vascular parkinsonism Bobamuratova, D.
113 S p.
 article
83 Diagnostic utility of whole-exome sequencing in early onset and familial Parkinson's disease: Preliminary findings in a regional centre study Rački, V.
113 S p.
 article
84 Difficulties in diagnosis of PSP Kadyrova, B.
113 S p.
 article
85 Disease severity and gait velocity are predictive of fear of falling avoidance behavior in people with parkinsonisms Landers, M.R.
113 S p.
 article
86 Dystonia 23: first report of a Colombian case García-Orjuela, D.
113 S p.
 article
87 Early onset dementia with parkinsonism in a patient with pathogenic mutations in CSF1R and ABCD1 gene Novotni, G.
113 S p.
 article
88 Early onset hemichorea-parkinsonism with POLG mutation without external ophthalmoplegia responsive to pallidal DBS Garrì, F.
113 S p.
 article
89 EEG findings in Gilles de la Tourette syndrome Rajczewska-Oleszkiewicz, C.
113 S p.
 article
90 Effect of istradefylline dosage on unified Parkisons’ disease rating scale (UPDRS) III-ON scores: results from four randomized clinical trials Kulisevsky, J.
113 S p.
 article
91 Effect of ventricular metrics on the treatment response in Parkinson’s disease Lee, J.-J.
113 S p.
 article
92 Effects of botulinum toxin type A in Meige's syndrome Duarte, A.
113 S p.
 article
93 Effects of levodopa on functional connectivity in Parkinson’s disease patients with Mild Cognitive Impairment Sreenivasan, K.
113 S p.
 article
94 Efficacy of incobotulinumtoxinA in subjects with sialorrhea, assessed using the modified Radboud Oral Motor inventory for Parkinson’s disease (mROMP) Jost, W.
113 S p.
 article
95 Eleven-year outcomes from the deep brain stimulation in early-stage Parkinson’s disease pilot clinical trial Hacker, M.
113 S p.
 article
96 Evaluation of extrapyramidal diseases with Parkinson’s disease in patients suffering from stroke in Tashkent region, Uzbekistan Sabirov, J.
113 S p.
 article
97 Evaluation of the adaptive capacity of patients with Prakinson's disease Djalilova, S.
113 S p.
 article
98 Exploration of the Immune-related genes Signatures and potential Molecular Mechanisms shared between AD and PD zhou, k.
113 S p.
 article
99 Fears and certainties of chilean neurologists in the therapeutic approach to parkinson's disease Salles, P.
113 S p.
 article
100 Feasibility of large-scale systematic data collection in a quality improvement registry of deep brain stimulation in Parkinson’s disease Jimenez-Shahed, J.
113 S p.
 article
101 Features of MRI signs in patients with Parkinson's disease Ismatov, A.
113 S p.
 article
102 Features of the specific clinical manifestations of vascular disorders in Parkinson's disease and vascular parkinsonism Akramova, D.
113 S p.
 article
103 Fingolimod-responsive complex hyperkinetic movement disorder in neuromyelitis optica spectrum disorder Cortes, R.E.
113 S p.
 article
104 Functional chorea diagnosed in a patient with schizophrenia treated with paliperidone: extrapyramidal side effect or functional? Kucukdagli, F. Erdogan
113 S p.
 article
105 Generalized dystonia of early onset associated with a homozygous loss-of-function variant in the AOPEP gene Fevga, C.
113 S p.
 article
106 Genetic heterogeneity on sleep disorders in Parkinson’s disease: a systematic review and meta-analysis Huang, J.
113 S p.
 article
107 Genetic screening of the LRRK2 G2019S mutation in the population of the South-West of Morocco Ait Wahmane, S.
113 S p.
 article
108 Genomic analyses of a large Swedish multi-incident kindred with autosomal dominant Parkinson’s disease with dementia Ygland Rödström, E.
113 S p.
 article
109 Gray matter abnormalities in myotonic dystrophy type 1: a voxel-wise meta-analysis Jiang, Q.
113 S p.
 article
110 Green tea intake and Parkinson's disease progression: a Mendelian randomization study Li, C.
113 S p.
 article
111 GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase show evidence of pharmacological efficacy in models of Parkinson’s disease Guzman, B.
113 S p.
 article
112 Heads - It's Parkinson’s; tails - it's cancer, a kindred of Parkinsonism and Malignancies Matta, M.
113 S p.
 article
113 Head-to-head comparison of [18F]-FDOPA PET and [123I]-FP-CIT SPECT for assessing nigrostriatal degeneration in patients with a clinically uncertain parkinsonian syndrome Wallert, E.
113 S p.
 article
114 Health-related quality of life in cervical dystoniausing EQ-5D-5L: a large cross-sectional study in China Lin, J.
113 S p.
 article
115 Health-related quality of life in multiple system atrophy using EQ-5D-5L: a large cross-sectional study in China Xiao, Y.
113 S p.
 article
116 Heat-induced tic reduction in Gilles de la Tourette syndrome Durbin, A.
113 S p.
 article
117 Hemorrhagic risk in patients who undergo deep brain stimulation on chronic antiplatelet or anticoagulation therapy Jackson, L.
113 S p.
 article
118 Heterogeneity in phenotypical and treatment response in a cohort of normal pressure hydrocephalus patients Di Maio, A.
113 S p.
 article
119 Hippocampal and amygdala atrophy rates correlate with the severity of sleep apnoea in Parkinson's disease Burdová, K.
113 S p.
 article
120 Homologs and order of duplication of insulin-like growth factor in humans Venger, A.
113 S p.
 article
121 How choroidal thickness is related with Parkinson’s disease? A case control study Fatima, A.
113 S p.
 article
122 Identification of suboptimal response to STN-DBS in Parkinson’s disease Rektor, I.
113 S p.
 article
123 Idiopathic NPH patients with worse pre-surgical walk test performances demonstrate the greatest improvement in performance post-VPS Kundrick, A.
113 S p.
 article
124 If not insulin resistance so what? Comparison fasting glycaemia in idiopathic Parkinson's disease and atypical parkinsonism Chmiela, T.
113 S p.
 article
125 Impact of COVID-19 pandemic on eating behavior and body mass index in patients with Parkinson's disease of Northeastern México Lopez-Botello, C.K.
113 S p.
 article
126 Impact of injection guidance techniques on the efficacy and safety of incobotulinumtoxinA for sialorrhea Jost, W.
113 S p.
 article
127 Impact of telemedicine among Parkinson’s disease patients during COVID-19 pandemic in Nepal Ojha, R.
113 S p.
 article
128 Improving the accuracy of DBS and other stereotactic neurosurgeries using a 3D-printed skull for preoperative target practice Singh, H.
113 S p.
 article
129 IncobotulinumtoxinA injections at intervals <10 weeks are effective and safe for cervical dystonia patients with inadequate benefit from standard intervals Comella, C.
113 S p.
 article
130 In-silico characterization of disease-associated missense mutation impairing frataxin function in Friedreich’s ataxia Singh, H.N.
113 S p.
 article
131 In silico study of Orexin on subthalamic nucleus neuron electrophysiology towards Parkinson’s disease Mahapatra, C.
113 S p.
 article
132 Interaction lead neurotoxicity and Parkinson’s disease In vivo study Mostefa, N.
113 S p.
 article
133 Intraoperative quantification of MDS-UPDRS tremor measurements using 3D accelerometry Smid, A.
113 S p.
 article
134 Invivo and invitro effects of resveratrol in experimental models of Parkinson's disease Kumar, R.
113 S p.
 article
135 Isolated lingual dystonia as a presenting symptom of X-linked dystonia parkinsonism Dakay, D.
113 S p.
 article
136 ¿It Is Any Difference Between Directional Vs Omnidirectional Lead For Treatment In Parkinson Disease? Bernal-Pacheco, O.
113 S p.
 article
137 Klazomania in Gilles de la Tourette syndrome Kaczyńska, J.
113 S p.
 article
138 Late-onset cerebellar ataxia: case report of a new CNV on TTBK2 gene as possible cause of SCA-11 Rodriguez, I.
113 S p.
 article
139 L-Dopa responsiveness in Perry syndrome (parkinsonism, depression, weight loss, hypoventilation) Dulski, J.
113 S p.
 article
140 Leigh-like syndrome as a presentation of biallelic variants in DNAJC30 gene with predominant putamen degeneration and limb dystonia Krygier, M.
113 S p.
 article
141 Leucine-rich repeat kinase2 (LRRK2) associated Parkinson's disease: less vulnerable during Covid-19 pandemic? Gharbi, A.
113 S p.
 article
142 “Levine-Critchley syndrome” - obsolete Danek, A.
113 S p.
 article
143 Levodopa-Carbidopa intestinal gel may improve treatment-resistant freezing of gait Shackleford, M.
113 S p.
 article
144 Levodopa-induced frequency modulation of cortical EEG activity in the supplementary motor area of dyskinetic Parkinson’s disease patients Avantaggiato, F.
113 S p.
 article
145 Lipid profile as a differentiating factor in PSP-Richardson-Steele syndrome and Corticobasal syndrome Madetko, N.
113 S p.
 article
146 Local field potential and clinical symptoms of Parkinson’s disease patients implanted with adaptive deep brain stimulation Oyama, G.
113 S p.
 article
147 Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks Jost, W.
113 S p.
 article
148 Long-term motor and non-motor symptom benefits in patients with advanced Parkinson's disease treated with Levodopa-Carbidopa Intestinal Gel: DUOGLOBE final analysis Chaudhuri, K.R.
113 S p.
 article
149 Long-term motor and non-motor symptom benefits of levodopa-carbidopa intestinal gel by baseline Hoehn & Yahr stage: DUOGLOBE post hoc analysis Pontieri, F.E.
113 S p.
 article
150 Long-term safety of continuous levodopa/carbidopa infusion with ND0612: results from the ongoing BeyoND study Poewe, W.
113 S p.
 article
151 Malnutrition status and cognitive functions correlation in patients with Parkinson's disease and atypical parkinsonisms: a preliminary study Ferri, V.
113 S p.
 article
152 Marked worsening of hypophonia, dysphagia and sialorrhea S/P bilateral STN DBS: a case report. Papesh, K.
113 S p.
 article
153 Metabolic changes in dementia with Lewy bodies and Parkinson’s disease Perovnik, M.
113 S p.
 article
154 Model of virtual communication of the Reference center for invasive methods of treatment of Parkinson's disease during the COVID-19 pandemic Komen, V.
113 S p.
 article
155 Mode of action of the neurotrophic factor CDNF as a potential drug for Parkinson's disease Kovaleva, V.
113 S p.
 article
156 Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine Sławek, J.
113 S p.
 article
157 Mortality risk associated with pimavanserin for hallucinations and delusions associated with Parkinson’s disease psychosis Isaacson, S.
113 S p.
 article
158 Moving toes in 28-year-old woman: a video case report Rajczewska-Oleszkiewicz, C.
113 S p.
 article
159 Mutation screening and burden analysis of IMPDH2 in dystonia in a Chinese population Lin, J.
113 S p.
 article
160 Necessity and feasibility of remote tele-programming of deep brain stimulation systems in Parkinson’s disease Esper, C.
113 S p.
 article
161 Neuroprotective and antioxidant potential of Moringa oleifera leaf extract in a murine model of Parkinson's disease Kumar, A.
113 S p.
 article
162 Neuroprotective effects of estradiol and progesterone in brain of different age groups of naturally menopausal rats.: a therapeutic potential drug for Parkinson’s disease Kumar, P.
113 S p.
 article
163 Neuroprotective effects of Ibudilast, a phosphodiesterase IV inhibitor in mouse model of Parkinson’s disease Sarswati, M.
113 S p.
 article
164 Nicotinamide riboside alleviates Parkinson's disease symptoms but downregulates dopamine metabolism Turconi, G.
113 S p.
 article
165 Non-motor manifestations of myoclonus dystonia on a mixed-ethnicity Filipino female with a novel sgce gene nonsense mutation: a case report De Leon, M.A.
113 S p.
 article
166 Non-motor symptoms in cervical dystonia Tur, E. Kobak
113 S p.
 article
167 Non-permitted food colorants induced cognitive impairment and neurotoxicity in hippocampus of rats Biswas, P.
113 S p.
 article
168 Obstructive Sleep Apnea (OSA) detection system based on Fast Fourier Transform (FFT) algorithm on electrocardiogram Fajar, R.
113 S p.
 article
169 OCT in Parkinson disease Sankaranaraynan, L.
113 S p.
 article
170 Olfactory dysfunction and severity of tremor - is there a connection? Pokhabov, D.D.
113 S p.
 article
171 Optimization of recruitment for movement disorders clinical trials in a pandemic: a single center experience Phillips, O.
113 S p.
 article
172 Optimizing CNS-Delivery by Lactyl Stearate-Coupled Liposomes Bhargava, M.
113 S p.
 article
173 Orthostatic hypotension: a mini-review Ovchynnykova, A.
113 S p.
 article
174 Orthostatic hypotension - insidious onset of MCA-C Stojkovska, F.
113 S p.
 article
175 Pain reduction in adult patients with limb spasticity following single incobotulinumtoxinA injection: analysis of pooled data from phase 2/3 studies Wissel, J.
113 S p.
 article
176 Paralogs and order of duplication of serotonin 1A receptor in humans Venger, O.
113 S p.
 article
177 ParkinsonGoesDTx – a novel gait monitor concept triggers treatment decisions in Parkinson’s disease Gladow, T.
113 S p.
 article
178 Patient perspective in hereditary ataxia Gorcenco, S.
113 S p.
 article
179 Patients’ with Parkinson disease perceptions of palliative care Kundrick, A.
113 S p.
 article
180 Phenotypic spectrum of progressive supranuclear palsy: clinical study and APOE effect Gharbi, A.
113 S p.
 article
181 Physical interventions for people with Parkinson's disease: results from a Cochrane systematic review and network meta-analysis Ernst, M.
113 S p.
 article
182 Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea Jost, W.
113 S p.
 article
183 Placebo-controlled study of neurophysiological parameters dynamics in patients with Parkinson's disease stage II after a course of transcranial magnetic stimulation Aravitskaya, D.
113 S p.
 article
184 PLA2G6-associated neurodegeneration in three different populations-case series Milanowski, L.
113 S p.
 article
185 Plasma miR-153 and miR-223 levels as potential biomarkers in Parkinson's disease Chen, W.
113 S p.
 article
186 Polygenic resilience inheritance modulates the penetrance of Parkinson’s disease genetic risk factors LIU, H.
113 S p.
 article
187 Polysomnographic study: characteristics of sleep disturbances in patients with Parkinson's disease Kurbonov, S.
113 S p.
 article
188 Population pharmacokinetics model of apomorphine (sublingual film or subcutaneous injection) in healthy subjects and patients with Parkinson’s disease (updated) Agbo, F.
113 S p.
 article
189 Population pharmacokinetics of levodopa and carbidopa following subcutaneous infusion Birnberg, T.
113 S p.
 article
190 Possible impact of subthalamic deep brain stimulation on glycemic variability and lipid profile in patients with Parkinson's disease Samborska-Ćwik, J.
113 S p.
 article
191 Possible link between cognition and motor reserve in patients with Parkinson’s disease Chung, S.J.
113 S p.
 article
192 Preclinical diagnosis of Parkinson’s disease: upgraded and new approaches Ugrumov, M.
113 S p.
 article
193 Prediction of Parkinson’s disease with dual-phase [18F] FP-CIT PET image through deep learning algorithm Cheon, S.-M.
113 S p.
 article
194 Predictors of early neurological deterioration in Wilson’s disease Litwin, T.
113 S p.
 article
195 Preliminary verification of a Kinect-based system for evaluating postural abnormalities in patients with Parkinson’s disease Hong, R.
113 S p.
 article
196 Prevalence and associated factors of malnutrition in patients with Parkinson's disease using CONUT and GNRI Jiang, Z.
113 S p.
 article
197 Prevalence and clinical correlations of Non-Motor Symptoms in patients with Ataxia: Study in a cohort of Mexican patients Pacheco, H.
113 S p.
 article
198 Prevalence of essential tremor in rural Gujarat, India Desai, S.
113 S p.
 article
199 Probabilistic tractography based structural connectivity of the tremor network in tremor dominant Parkinson’s disease and essential tremor plus syndrome Prasad, S.
113 S p.
 article
200 Progressive supranuclear palsy Skenderoska, I.
113 S p.
 article
201 Progressive Supranuclear Palsy Parkinsonism-Predominant (PSP-P) – a problematic entity in the examination of parkinsonisms Alster, P.
113 S p.
 article
202 Protective potential of cinnamaldehyde and genistein against aluminium-induced neurotoxicity in male rats Rajput, S.
113 S p.
 article
203 Quality of life and affective disorders of patients with Parkinson`s disease and chronic pain Stepanchenko, K.
113 S p.
 article
204 Rare neurological indications for Deep Brain Stimulation treatment: experience at the University Medical Center Ljubljana Ibrulj, S.
113 S p.
 article
205 Real-world effect of age on long-term effectiveness and safety of levodopa-carbidopa intestinal gel: post hoc analysis from the DUOGLOBE study Simu, M.
113 S p.
 article
206 Refractory progressive catatonia in autism spectrum disorder Brasic, J.
113 S p.
 article
207 Relationship between risk and protective factors and clinical features of Parkinson’s disease Costanzo, M.
113 S p.
 article
208 Reliability and validity study of a Turkish version of the Sialorrhea Clinical Scale for Parkinson’s disease (SCS-TR) Sapmaz Atalar, M.
113 S p.
 article
209 REM sleep behavior disorder correlates with constipation in de novo Chinese Parkinson's disease patients Chen, Y.
113 S p.
 article
210 Reprogramming frequency in clinical practice: 6-months post-implantation of DBS for Parkinson’s disease subjects in ADROIT Groppa, S.
113 S p.
 article
211 SAGE-718 in Parkinson's disease mild cognitive impairment: results from the Phase 2 PARADIGM Study Koenig, A.
113 S p.
 article
212 Sarcopenia in acute ischemic stroke patients and patients with Parkinson’s disease Mandjikoska, S.
113 S p.
 article
213 Setting the TEMPO: A phase 3 program to investigate tavapadon, a selective D1/D5 partial agonist, for Parkinson’s disease Fernandez, H.F.
113 S p.
 article
214 Spastic ataxic phenotype of Fatty acid 2-hydroxylase associated neurodegeneration: a case series from India Holla, V.V.
113 S p.
 article
215 Speech-induced lower face dystonia – presentation of two cases Kaczyńska, J.
113 S p.
 article
216 STN DBS improves balance disorders in Parkinson’s disease patients and impacts the disease progression Szlufik, S.
113 S p.
 article
217 Structural and functional brain abnormalities in idiopathic cervical dystonia: a multimodal meta-analysis Huang, X.
113 S p.
 article
218 Structural Cerebellar Lobules Correlates of Dystonic Head Rotation in Idiopathic Cervical Dystonia m. Qiu,
113 S p.
 article
219 Study of the difficulties of late diagnostics in patients with Huntington’s disease in Uzbekistan Ismatov, A.
113 S p.
 article
220 Subthalamic recordings in chronically implanted parkinsonian patients Palmisano, C.
113 S p.
 article
221 Sustained release triple drug loaded colloidosomes for management of Parkinson’s disease Bhargava, S.
113 S p.
 article
222 Switching and combining device-aided therapies in advanced Parkinson’s disease: a double centre retrospective study Delalić, S.
113 S p.
 article
223 Symptomatic relief of constant groaning in progressive supranuclear palsy with escitalopram Quiñones, C.P.
113 S p.
 article
224 The conjugacy of migraine and parkinsonism, from theory to practice Panoeva, N.
113 S p.
 article
225 The distinctive functional connectivity of the cholinergic nucleus basalis of Meynert in Parkinson’s disease across different cognitive status Nazmuddin, M.
113 S p.
 article
226 The effects of once-daily opicapone 50 mg on the pharmacokinetics of levodopa administered as carbidopa/levodopa extended-release capsules: an open-label study Klepitskaya, O.
113 S p.
 article
227 The feasibility of using loss of “swallow tail sign” on 3T – susceptibility weighted MRI in diagnosis of Parkinson’s disease Ha, U.N.L.
113 S p.
 article
228 The impact of non motor symptoms on quality of life in patients with young onset Parkinson’s disease Abdurakhmonova, K.
113 S p.
 article
229 The need to include functional movement disorders in the differential diagnosis of children presenting to emergency departments Brasic, J.
113 S p.
 article
230 The role of dopaminergic therapy on cognition in Parkinson’s disease Montaser Kouhsari, L.
113 S p.
 article
231 The role of vascular factors in Parkinson's disease and vascular parkinsonism Khamdamov, S.-J.
113 S p.
 article
232 Tissue biomarker for the detection of dementia with Levi bodies Azizova, D.
113 S p.
 article
233 Treatment of cervical dystonia using shorter incobotulinumtoxinA injection intervals improves patient-reported outcomes in those with inadequate benefits from standard intervals Comella, C.
113 S p.
 article
234 Understanding correlation between diffusion MRI-derived white-matter organization and clinical measures in Parkinson’s disease patients with freezing of gait Mishra, V.
113 S p.
 article
235 Understanding correlation between diffusion MRI-derived white-matter organization and neuropsychological measures in Parkinson’s disease patients with freezing of gait Mishra, V.
113 S p.
 article
236 Using Non-Exercise-Physical-Activity to preserve post-Physical Therapy gains in Parkinson's disease: a feasibility study van Emde Boas, M.
113 S p.
 article
237 Utilizing technology-based outcome measures in the natural setting to answer intriguing clinical questions in Parkinson disease Phillips, O.
113 S p.
 article
238 Validation of patient administered psychosis questionnaire for screening Parkinson’s disease patients for psychosis. Koneru, V.
113 S p.
 article
239 Vestibular dysfunction: which is the effects of virtual reality? Simone Zeigelboim, B.
113 S p.
 article
240 Video-based analysis of gait in Parkinson disease Jeon, B.
113 S p.
 article
241 Violation of motor and non-motor functions in patients with COVID-19 with oral pathology Giyazova, M.
113 S p.
 article
242 Vodobatinib, a potent, orally bioavailable brain-penetrating inhibitor of c-Abl as a potential neuroprotective agent for treatment of Parkinson disease Walsh, R.R.
113 S p.
 article
243 White matter connectivity networks predict early dementia conversion in Parkinson’s disease Chung, S.J.
113 S p.
 article
244 Whole exome sequencing of familial, combined or complex dystonia Kafantari, E.
113 S p.
 article
                             244 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands